History
Cambrex was founded in 1981, when the CasChem group acquired the castor oil and derivatives product lines from NL Industries. In 1987, CasChem was renamed Cambrex Corporation and became listed on NASDAQ. Cambrex entered the pharmaceutical market in 1994 with the acquisition of Nobel Pharma Chemistry business, now known as Cambrex Karlskoga AB and Cambrex Profarmaco. Through multiple acquisitions during the late 1990s, Cambrex entered the bioscience and the chiral enzymatic catalyst markets. In 1998, Cambrex was listed on the NYSE. Cambrex acquired two contract biopharmaceutical manufacturing facilities, in 2001, to bulk manufacture biologics and pharmaceutical ingredients from clinical to commercial scales. In 2007, Cambrex decided to focus on its core competencies and sold the biologics business to Lonza Group. In 2008, Prosyntest (now Cambrex Tallinn) was acquired, and Steve Klosk was appointed CEO, while remaining President. To broaden their biocatalysis platform, Cambrex acquired IEP, now known as Cambrex IEP. In November 2010, Cambrex acquired a 51% stake in Zenara Pharma, providing vertical integration with Zenara's cost-effective formulation and finished dosage form capabilities.
Read more about this topic: Cambrex Corporation
Famous quotes containing the word history:
“Every literary critic believes he will outwit history and have the last word.”
—Mason Cooley (b. 1927)
“Indeed, the Englishman’s history of New England commences only when it ceases to be New France.”
—Henry David Thoreau (1817–1862)
“Like their personal lives, women’s history is fragmented, interrupted; a shadow history of human beings whose existence has been shaped by the efforts and the demands of others.”
—Elizabeth Janeway (b. 1913)